# A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Source: https://onco.cc/trials/nct06501196/  
OnCo record `nct06501196` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BH-30236 run by BlossomHill Therapeutics, now recruiting.

## Summary

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome is a phase 1 interventional study registered as NCT06501196 by BlossomHill Therapeutics, with 170 participants planned, started 2024-06-19. Conditions recorded: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes and Refractory Acute Myeloid Leukemia. Interventions recorded: BH-30236 and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06501196
- Phase: 1
- Setting: A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Sponsor: BlossomHill Therapeutics
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT06501196: https://clinicaltrials.gov/study/NCT06501196

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [BH-30236](https://onco.cc/drugs/bh-30236/)
- companies: [BlossomHill Therapeutics](https://onco.cc/companies/blossomhill-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06501196.json